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Abstract
Background: Biomarkers that could predict malignant transformation of recurrent
respiratory papillomatosis (RRP) would be useful in patient follow-up. We investi-
gated whether serum matrix metalloproteinase 8 (MMP-8) and tissue inhibitor of
metalloproteinase 1 (TIMP-1) could predict malignant transformation of RRP and
whether they associate with survival in laryngeal squamous cell carcinoma (LSCC)
without preexisting RRP.
Methods: We analyzed serum MMP-8 (S-MMP-8) and serum TIMP-1 (s-TIMP-1)
in 114 patients: 55 were treated for RRP and 59 for LSCC without preexisting
RRP. Five patients with RRP developed LSCC during follow-up.
Results: Elevated S-MMP-8 level in RRP was associated with malignant transforma-
tion (P = .01). Compared to patients with RRP, S-MMP-8 in patients with LSCC was
significantly higher (P < .001). Increased S-TIMP-1 level in LSCC was associated
with poor overall survival (P = .02) and recurrence-free survival (P = .05).
Conclusion: In RRP, high S-MMP-8 may predict malignant transformation. In
LSCC, elevated S-TIMP-1 is connected to poor survival.
KEYWORDS
biomarkers, laryngeal carcinoma, MMP-8, recurrent respiratory papilloma,
TIMP-1
1 | INTRODUCTION
Recurrent respiratory papillomatosis (RRP) is a disease char-
acterized by recurrent benign epithelial tumors that typically
present in the larynx. The main causative agents are low-risk
human papillomavirus (HPV) types 6 and 11.
Matrix metalloproteinases (MMPs) are genetically dis-
tinct but structurally related proteolytic enzymes, which can
modulate the degradation of extracellular matrix components
and basement membranes. They also modulate inflammatory
responses by processing various nonmatrix bioactive sub-
sites such as growth factors, pro-inflammatory and antiin-
flammatory cytokines. MMP-8 degrades collagen type 1. It
is also associated with many inflammatory conditions. Nur-
menniemi et al. have shown that in patients with head and
neck squamous cell carcinoma, elevated plasma MMP-8
levels are associated with stage IV disease.1 Tissue inhibitors
of metalloproteinases (TIMPs) regulate the activity of
MMPs, and in addition they function as growth factors.2
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Overall survival (OS) in patients with head and neck cancer
with enhanced systemic TIMP-1 response is poor.1,3,4 How-
ever, the survival rates have not been reported independently
by primary tumor site.
Our previous study combined data of patients with RRP
from the Helsinki University Hospital database and the Finn-
ish Cancer Registry. We showed that 9 of 324 (2.8%)
patients with RRP, treated between 1975 and 2011, devel-
oped laryngeal squamous cell carcinoma (LSCC).5 The aim
of this study was to further analyze this patient group and to
assess whether S-MMP-8 and S-TIMP-1 could predict
malignant transformation of RRP. Moreover, we compared
S-MMP-8 and S-TIMP 1 levels of patients with RRP and
LSCC and analyzed whether the serum levels in patients
with LSCC were associated with survival.
2 | PATIENTS AND METHODS
2.1 | Patients
2.1.1 | Recurrent respiratory papillomatosis
We included all patients with RRP who had donated serum
between 1996 and 2004 for the Helsinki University Hospital
Head and Neck Tumor Bank and were aged 40 years or older
when the serum samples were drawn. National Cancer Registry
data confirmed all malignancies diagnosed before the year
2012. Of the 55 patients (median age 55 years, range 40-77,
76% males), 5 developed LSCC (Table 1). Formalin-fixed
paraffin-embedded laryngeal tissue blocks from patients with
RRP who developed LSCC were retrieved from the archives of
the Department Pathology and processed for standard hematox-
ylin and eosin–stained sections. The study pathologist (J.K.H.)
carefully assessed the stained sections, and papilloma histology
with koilocytes, parakeratosis/hyperkeratosis, and papilloma-
tous epithelium with a fibrovascular core was confirmed using
stringent criteria.6 Between January 2012 and October 2017,
16 of the 55 patients (29%) had undergone follow-up examina-
tion, but no additional malignancies were diagnosed.
2.1.2 | LSCC without preexisting RRP
To analyze whether S-MMP-8 and S-TIMP-1 levels were simi-
lar in RRP and LSCC, and to evaluate association between
serum values and LSCC survival, we included 59 patients with
LSCC (median age 66 years, range 26-88) without preexisting
RRP (Table 2). These patients had donated serum for the Hel-
sinki University Hospital Head and Neck Tumor Bank at the
time of diagnosis. All study patients were treated with curative
intent. T1 tumors were primarily treated with a single modality,
either surgery or radiotherapy. Of the 29 patients with T2-T3
tumors, 19 (66%) were treated with chemoradiotherapy,
5 (17%) with radiotherapy, 4 (14%) with surgery followed by
radiotherapy or chemoradiation, and 1 (3%) with surgery only.
Of the 11 patients with T4 tumors, 8 (73%) underwent total lar-
yngectomy followed by either radiotherapy or chemoradiation,
whereas 3 (27%) underwent chemoradiotherapy only. Dates of
death were provided by the Finnish Population Registry
Center.
Radiotherapy was conventional external beam radiation
therapy or intensity-modulated radiation therapy. Chemo-
therapeutic regimens were platinum-based agents given con-
comitantly with radiotherapy. Patients with distant
metastases and those scheduled for palliative treatment at the
time of presentation were excluded.
OS was defined as the duration from diagnosis to death
from any cause, recurrence-free survival (RFS) from diagno-
sis to first documented recurrence, and disease-specific sur-
vival (DSS) from diagnosis to death caused by LSCC.
The Ethics Committee of Surgery in the Hospital District
of Helsinki and Uusimaa approved the study, and all patients
gave their informed written consent. Institutional permission
was granted.
2.2 | Serum MMP-8 and TIMP-1 analyses
Serum samples were centrifugated, and the supernatants
were stored at −70C. Time-resolved immunofluorometric
assay was used to determine S-MMP-8 concentrations, as
described earlier.7,8 A commercially available enzyme-
linked immune sorbent assay (Amersham Biosciences UK
Ltd, Buckinghamshire, United Kingdom) was used to deter-
mine S-TIMP-1 concentrations. The detection limit was
1.25 ng/mL for TIMP-1 and 0.8 ng/mL for MMP-8. The
levels of MMP-8 and TIMP-1 were expressed as nanograms
per milliliter; for calculation of MMP-8/TIMP-1 molar
ratios, the levels were converted to moles per liter.
2.3 | Statistical analyses
SPSS Statistics 20.0 (IBM, Armonk, New York) was used
for statistical analyses. Mann-Whitney U test was used to
TABLE 1 Clinical characteristics of 5 male patients with RRP
transforming into LSCC
Characteristics Values
No. of male patients (%) 5 (100)
Age (y) at RRP diagnosis, median (range) 60 (4-73)
No. of laryngeal procedures before LSCC, median (range) 6 (3-18)
Duration (y) of RRP before LSCC, median (range) 7 (3-63)
Time (y) from obtaining the serum sample
until LSCC, median (range)
5 (0.7-6.6)
Age (y) at LSCC diagnosis, mean (range) 68 (57-80)
T classification, no. of patients
Tis 1
T1 3
T2 0
T3 1
T4 0
Abbreviations: LSCC, laryngeal squamous cell carcinoma; RRP, recurrent respi-
ratory papillomatosis; Tis, tumor in situ.
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compare serum concentrations between any 2 groups. Pear-
son correlation test was used to analyze correlations between
serum values and age. Kaplan-Meier method and log rank
test served to compare association between serum values
and survival in patients with LSCC. Patients with LSCC
were classified according to their serum concentrations, so
that the highest quintile, 3 middle quintiles, and the lowest
quintile comprised 3 groups for comparison. Cox regression
was used to analyze whether log10 transformed serum
values, adjusted for age, sex, and stage (I-II vs III-IV), were
independently associated with survival. Statistically signifi-
cant P value was set at .05.
3 | RESULTS
In total, this study comprised 114 patients of whom 55 were
primarily treated for RRP and 59 for LSCC without preexisting
RRP. Clinical characteristics of 5 patients with RRP who
developed LSCC are presented in Table 1, and those of the
59 patients treated for LSCC without preexisting RRP are pre-
sented in Table 2. Of the 59 patients with LSCC, 30 (51%) sur-
vived, and their mean duration of follow-up was 6.7 years
(range 0.9-10.8 years). Of the 59 patients, 13 (22%) developed
a disease recurrence. Five of the 13 recurrences were success-
fully treated with curative intent, either surgery (n = 4) or
radiotherapy (n = 1), whereas 8 of the 13 had either distant
metastases or locally advanced nonoperable disease. Five-year
OS in patients with LSCC without preexisting RRP was 73%,
RFS was 83%, and DSS was 88%.
3.1 | Serum MMP-8 and TIMP-1 in RRP and LSCC
Compared to patients with RRP, those treated for LSCC with-
out preexisting RRP were seen with significantly higher S-
MMP-8 (mean 35.0 vs 116.1 ng/mL, P < .001) but the differ-
ences in S-TIMP-1 were nonsignificant (141.3 vs 153.8 ng/
mL, P = .50). Patients with LSCC also had significantly higher
MMP-8/TIMP-1 molar ratio than patients with RRP (0.40 vs
0.11, P < .001). The comparison of serum values is presented
in Table 3. Correlation between the serum values and age was
insignificant in both RRP and LSCC.
TABLE 2 Clinical characteristics of 59 patients with LSCC without
preexisting RRP
Characteristics Values
No. of male patients (%) 50 (85)
Age (y) at LSCC diagnosis, median (range) 66 (26–88)
Smoking, no. of patients (%)
Yes 53 (90)
No 4 (7)
NA 2 (3)
Subsite, no. of patients (%)
Glottic or several subsites 51 (86)
Supraglottic 7 (12)
Subglottic 1 (2)
Histological grade, no. of patients (%)
Grade 1 13 (22)
Grade 2 26 (44)
Grade 3 7 (12)
Anaplastic 1 (2)
NA 12 (20)
T classification, no. of patients (%)
T1 19 (32)
T2 14 (24)
T3 15 (25)
T4 11 (19)
Stage, no. of patients (%)
I-II 31 (53)
III-IV 28 (47)
Primary treatment, no. of patients (%)
Surgery only 13 (22)
Radiotherapy only 12 (20)
Chemoradiotherapy only 22 (37)
Surgery + radiotherapy 9 (15)
Surgery + chemoradiotherapy 3 (5)
Abbreviations: LSCC, laryngeal squamous cell carcinoma; NA, not available;
RRP, recurrent respiratory papillomatosis.
TABLE 3 S-MMP-8 and S-TIMP-1 levels and MMP-8/TIMP-1 molar ratios among study groups
Patient group
S-MMP-8 (ng/mL),
mean (range) P-value
S-TIMP-1
(ng/mL), mean (range) P-value
MMP-8/TIMP-1 molar
ratio, mean (range) P-value
All study subjects (N = 114)
RRP (n = 55) 35.0 (7.2-115.6) <.001 141.3 (72.6-195.1) .50 0.11 (0.02-0.38) <.001
LSCC (n = 59) 116.1 (9.1-454.7) 153.8 (48.9-391.8) 0.40 (0.03-2.71)
RRP (n = 55)
RRP without malignant
transformation (n = 50)
31.5 (7.2-82.8) .01 142.5 (72.6-195.2) .23 0.10 (0.02-0.30) .009
RRP with malignant
transformation (n = 5)
70.1 (23.5-115.6) 129.4 (101.6-154.3) 0.23 (0.08-0.38)
LSCC (n = 59)
Stage I-II (n = 31) 91.7 (9.1–454.7) .01 150.8 (48.9–391.8) .63 0.35 (0.03-2.71) .03
Stage III-IV (n = 28) 143.1 (18.7-363.2) 157.1 (80.1-301.1) 0.46 (0.05-1.23)
Abbreviations: LSCC, laryngeal squamous cell carcinoma; RRP, recurrent respiratory papillomatosis; S-MMP-8, serum matrix metalloproteinase 8; S-TIMP-1, serum
tissue inhibitor of metalloproteinase 1.
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Interestingly, even patients with LSCC with T1 tumors
(n = 19) were seen with significantly higher S-MMP-8
(94.9 vs 35.0 ng/mL, P = .002) and MMP-8/TIMP-1 molar
ratio (0.40 vs 0.11, P = .01) than patients with RRP.
3.2 | Serum MMP-8 and TIMP-1 in RRP with
malignant transformation
Patients with RRP who later developed LSCC had signifi-
cantly higher S-MMP-8 levels than those without malignant
transformation (70.1 vs 31.5 ng/mL, P = .01). The differ-
ence was not significant for S-TIMP-1 (129.4 vs 142.5 ng/
mL, P = .23). Mean MMP-8/TIMP-1 molar ratio was 0.10
among patients with RRP without malignant transformation
and 0.23 with malignant transformation (P = .009). Patients
with RRP who later developed LSCC were not significantly
older than patients with RRP without malignancy (median
age 62 vs 54 years, P = .05) when the serum samples were
drawn. Figure 1 presents the comparison of S-MMP-8 in
RRP and LSCC.
3.3 | Serum MMP-8 and TIMP-1 without
preexisting RRP
Compared to patients with stage I-II LSCC, those seen with
stage III-IV disease had significantly higher S-MMP-8 (91.7
vs 143.1 ng/mL, P = .01) and MMP-8/TIMP-1 molar ratio
(0.35 vs 0.46, P = .03). S-TIMP-1 was not associated with
stage (150.8 vs 157.1 ng/mL, P = .63).
Univariate Kaplan-Meier analysis with log-rank test
showed that in LSCC without preexisting RRP, both S-
MMP-8 (P = .004) and S-TIMP-1 (P = .04) were signifi-
cantly associated with OS. Thus, in those patients seen with
the highest serum values, the prognosis was poor (Figure 2).
Multivariate analysis, adjusted for age, sex, and stage
(I-II vs III-IV), showed that log10 transformed values of
S-TIMP-1 were significantly associated with OS (P = .02)
and RFS (P = .05, Tables 4 and 5). Association between
FIGURE 1 Comparison of serum matrix metalloproteinase 8 (S-MMP-8)
in recurrent patients with respiratory papillomatosis (RRP) without
malignancy, in patients with RRP who developed laryngeal squamous cell
carcinoma (LSCC), and in patients with LSCC according to disease stage
[Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 A, Overall survival (OS) in 59 patients with laryngeal squamous cell carcinoma (LSCC) according to serum matrix metalloproteinase 8 (S-
MMP-8) and (B) tissue inhibitor of metalloproteinase 1 (S-TIMP-1) concentration. Patients were classified according to their serum concentrations so that the
highest quintile, 3 middle quintiles, and the lowest quintile comprised 3 groups for comparison [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 4 Cox regression analyses for overall survival in patients
with LSCC
Covariates HR 95% CI P-value
Age 1.05 1.01-1.10 .02
Sex 1.61 0.55-4.69 .38
Stage 2.28 0.94-5.54 .06
Log10MMP-8 1.32 0.75-2.34 .34
Log10TIMP-1 5.24 1.27-21.60 .02
Abbreviations: CI, confidence interval; HR, hazard ratio; log10MMP-8, log10
transformed serum matrix metalloproteinase 8; log10TIMP-1, log10 transformed
serum tissue inhibitor of metalloproteinase 1; LSCC, laryngeal squamous cell
carcinoma.
312 PAKKANEN ET AL.
S-TIMP-1 and DSS was only slightly beyond significance
(hazard ratio 12.0, 95% confidence interval 0.95-152.2,
P = .05). Log10 transformed values of S-MMP-8 or MMP-
8/TIMP-1 molar ratio did not correlate with any of the sur-
vival parameters in multivariate analyses.
4 | DISCUSSION
Compared to LSCC, S-MMP-8 levels in RRP were low. In
many inflammatory conditions, MMP-8 expression is upre-
gulated. Although RRP is caused by HPV infection, papillo-
mas are typically small lesions restricted to the vocal fold
epithelium. Weak systemic inflammatory response may
explain why S-MMP-8 levels in RRP remain low. Interest-
ingly, the patients who later developed LSCC had signifi-
cantly higher S-MMP-8 levels in comparison to patients
with RRP without malignancy. Thus, enhanced systemic
MMP-8 response in RRP may predict malignant transforma-
tion. Laryngeal papillomas undergoing malignant transfor-
mation may cause stronger host responses and production of
MMP-8. Premalignant dysplastic lesions of the larynx are
often accompanied by a varying degree of mucosal inflam-
mation. Elevated S-MMP-8 levels in patients with RRP
developing malignancy may have been associated with
laryngeal inflammation. Although this cannot be confirmed
in this retrospective material, the predictive role of MMP-8
in chronic laryngitis and precancerous laryngeal lesions is an
interesting target for future research. Traditional risk factors
for LSCC, smoking, and alcohol consumption are also risk
factors for chronic laryngitis, which may proceed to cancer.
Lauhio et al. found that smoking can increase S-MMP-8
concentration.9 In our study, smoking history was reported
in patients with LSCC but not in patients with RRP. Smok-
ing was not connected to MMP-8 and TIMP-1 serum levels
in patients with LSCC (data not shown).
Malignant transformation has different features among
patients with adult-onset RRP and juvenile-onset RRP. In
juvenile-onset disease, the patients who develop malignancy
are on average younger when diagnosed with RRP. They are
seen with an extremely aggressive disease where tracheal or
bronchial spread of papillomas is followed by squamous cell
carcinoma of the lung. In patients with adult-onset RRP, pre-
malignant lesions are typically limited to the larynx. Some
patients have characteristics resembling chronic laryngitis
with epithelial hyperplasia and hyperkeratosis. In adult-onset
RRP, patients with malignant transformation are on average
older when diagnosed with RRP, and they typically develop
LSCC. Inflammation and smoking may be cofactors in the
process of carcinogenesis, and the exact role of low-risk
HPV infection is yet unclear.10
One limitation of our study is that the number of patients
with RRP with malignant transformation is rather small. A
multicenter setting with a larger number of serum samples
would give power to our findings. Although RRP is a rare
disease, frequently recurring papillomas in a laryngological
practice are common. Biomarkers predicting malignant
transformation would be useful especially in patients with
RRP with long history of smoking, several recurrences, and
persisting dysplasia.
Our study agrees with the previous studies in that ele-
vated S-MMP-8 levels are associated with an advanced dis-
ease stage.1,11 For MMP-8, both tumor protective and tumor
promoting roles have been suggested.12–14 MMP-8 plays a
central role in inflammation; it is expressed not only by neu-
trophils but additionally by macrophages, monocytes,
T cells, plasma cells, fibroblasts, and epithelial cells.15 In
colorectal cancer, high S-MMP-8 value was associated with
stage IV disease and tumor necrosis.16 Elevated S-MMP-8
levels in our patients with stage III-IV disease may also be
associated with tumor necrosis or inflammatory response
induced by greater tumor volume. In our study, even patients
with small T1 tumors seen with significantly higher S-
MMP-8 levels than patients with benign laryngeal papillo-
mas. Serum biomarkers that could indicate the presence of
early stage tumors should be evaluated in upcoming studies,
considering their potential for cancer screening and early
detection of cancer recurrence.
We show that elevated S-TIMP-1 level can predict poor
OS in LSCC. Previous studies reporting association between S-
TIMP-1 and OS have included heterogeneous groups of head
and neck tumors, minority of them presenting in the larynx.1,3,4
Several factors unrelated to cancer, such as other chronic dis-
eases, may also affect OS. To our knowledge, this is the first
study reporting association between S-TIMP-1 and LSCC
recurrence. Ma et al. used immunohistochemistry to analyze
expression of TIMP-1 in 109 LSCC specimens. Positive stain-
ing was mainly localized in the cytoplasm of laryngeal cancer
cells, not in the adjacent normal tissues. Multivariate analyses
showed that high TIMP-1 expression and lymph node metasta-
ses may serve as independent prognostic factors for OS.17
Evidence is strong to conclude that in head and neck
cancer, TIMP-1 is associated with unfavorable prognosis.
TIMP-1 is a multifunctional protein that can promote cell
growth, inhibit apoptosis, and regulate angiogenesis.18 It
may thus promote tumor progression and dissemination by
TABLE 5 Cox regression analyses for recurrence-free survival in patients
with LSCC
Covariates HR 95% CI P-value
Age (y) 1.02 0.96-1.09 .50
Sex 1.10 0.22-5.40 .90
Stage 2.21 0.63-7.82 .21
Log10MMP-8 1.27 0.61-2.68 .52
Log10TIMP-1 6.93 1.00-48.17 .05
Abbreviations: CI, confidence interval; HR, hazard ratio; log10 MMP-8, log10
transformed serum matrix metalloproteinase 8; log10 TIMP-1, log10 transformed
serum tissue inhibitor of metalloproteinase 1; LSCC, laryngeal squamous cell
carcinoma.
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several molecular mechanisms. Because etiology and prog-
nosis of head and neck cancer differs considerably between
anatomical subsites, future studies should more specifically
report the expression of TIMP-1 in primary tumors by sub-
site, in adjacent nontumorous tissue, and in peripheral blood.
In univariate analyses, also high S-MMP-8 was associ-
ated with poor OS. However, this is likely to be explained
by stage III-IV diseases presenting with elevated S-MMP-8.
Nonetheless, it should be kept in mind that in former studies
S-MMP-8 concentration has not been connected to head and
neck cancer survival.1,4
Although our study provides new information about S-
MMP-8 and S-TIMP-1 levels' connections to malignant trans-
formation of RRP and LSCC prognosis, more studies are
needed to develop new diagnostic and prognostic tool for
clinical use.
ACKNOWLEDGMENTS
This study was funded by Helsinki University Hospital
research funds. We thank Tero Vahlberg, MSc, for his assis-
tance in statistical analyses.
ORCID
Pihla P. Pakkanen https://orcid.org/0000-0002-0009-8146
Taru T. Ilmarinen https://orcid.org/0000-0001-8674-6417
REFERENCES
1. Nurmenniemi S, Koivula M-KK, Nyberg P, et al. Type I and III collagen
degradation products in serum predict patient survival in head and neck
squamous cell carcinoma. Oral Oncol. 2012;48(1368–8375):136-140.
2. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-
promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a
wide range of cells. A possible new growth factor in serum. FEBS Lett.
1992;298(1):29-32.
3. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Tissue inhibitor of
matrix metalloproteinase-1 is prognostic in head and neck squamous cell
carcinoma: comparison of the circulating and tissue immunoreactive protein.
Clin Cancer Res. 2005;11(9):3257-3264.
4. Pradhan-Palikhe P, Vesterinen T, Tarkkanen J, et al. Plasma level of tissue
inhibitor of matrix metalloproteinase-1 but not that of matrix
metalloproteinase-8 predicts survival in head and neck squamous cell cancer.
Oral Oncol. 2010;46(7):514-518.
5. Ilmarinen T, Hagström J, Haglund C, et al. Low expression of nuclear toll-
like receptor 4 in laryngeal papillomas transforming into squamous cell car-
cinoma. Otolaryngol Head Neck Surg. 2014;151(5):785-790.
6. El-Naggar AK, Chan JKC, Rubin Grandis J, Takata T, Slootweg PJ. Pathol-
ogy and genetics of tumours of haematopoietic and lymphoid tissues. In:
Eble JN, Sauter G, Epstein JE, Sesterhenn IA, eds. WHO Classification of
Head and Neck Tumours. Vol 92. Lyon, France: IARC Press; 2017:832-
2415.
7. Hemmilä I, Dakubu S, Mukkala VM, Siitari H, Lövgren T. Europium as a
label in time-resolved immunofluorometric assays. Anal Biochem. 1984;
137(2):335-343.
8. Tuomainen AM, Nyyssönen K, Laukkanen JA, et al. Serum matrix
metalloproteinase-8 concentrations are associated with cardiovascular out-
come in men. Arterioscler Thromb Vasc Biol. 2007;27(12):2722-2728.
9. Lauhio A, Färkkilä E, Pietiläinen KH, et al. Association of MMP-8 with obe-
sity, smoking and insulin resistance. Eur J Clin Invest. 2016;46(9):757-765.
10. Karatayli-Ozgursoy S, Bishop JA, Hillel A, Akst L, Best SRA. Risk factors
for dysplasia in recurrent respiratory papillomatosis in an adult and pediatric
population. Ann Otol Rhinol Laryngol. 2016;125(3):235-241.
11. Kuropkat C, Duenne AA, Herz U, Renz H, Werner JA. Significant correla-
tion of matrix metalloproteinase and macrophage colony-stimulating factor
serum concentrations in patients with head and neck cancer. Neoplasma.
2004;51(5):375-378.
12. Stadlmann S, Pollheimer J, Moser PL, et al. Cytokine-regulated expression
of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer.
Eur J Cancer. 2003;39(17):2499-2505.
13. Gutiérrez-Fernández A, Fueyo A, Folgueras AR, et al. Matrix
metalloproteinase-8 functions as a metastasis suppressor through modulation
of tumor cell adhesion and invasion. Cancer Res. 2008;68(8):2755-2763.
14. Korpi J, Kervinen V, Mäklin H, et al. Collagenase-2 (matrix
metalloproteinase-8) plays a protective role in tongue cancer. Br J Cancer.
2008;98:766-775.
15. Dejonckheere E, Vandenbroucke RE, Libert C. Matrix metalloproteinase8
has a central role in inflammatory disorders and cancer progression. Cyto-
kine Growth Factor Rev. 2011;22(2):73-81.
16. Väyrynen JP, Vornanen J, Tervahartiala T, et al. Serum MMP-8 levels
increase in colorectal cancer and correlate with disease course and inflamma-
tory properties of primary tumors. Int J Cancer. 2012;131(4):E463-E474.
17. Ma J, Wang J, Fan W, et al. Upregulated TIMP-1 correlates with poor prog-
nosis of laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2014;
7(1):246-254.
18. Yoshiji H, Harris SR, Raso E, et al. Mammary carcinoma cells over-
expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular
endothelial growth factor expression. Int J Cancer. 1998;75(1):81-87.
How to cite this article: Pakkanen PP,
Aaltonen L-M, Sorsa TA, Tervahartiala TI,
Hagström JK, Ilmarinen TT. Serum matrix metallo-
proteinase 8 and tissue inhibitor of metalloproteinase
1: Potential markers for malignant transformation of
recurrent respiratory papillomatosis and for prognosis
of laryngeal cancer. Head & Neck. 2019;41:309–314.
https://doi.org/10.1002/hed.25459
314 PAKKANEN ET AL.
